Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer

Akira Matsui, Akihiko Tatibana, Noriyuki Suzuki, Masaru Hirata, Yoko Oishi, Youhei Hamaguchi, Yuya Murata, Aiko Nagayama, Yuko Iwata, Yasushi Okamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m2) for human epidermal growth factor 2 (HER2)-negative breast cancer. Patients and Methods: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m2 Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended. Results: From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1% [95% confidence interval(CI)=47.2% to 71.0%), 63.6% in those with hormone receptor-positive tumors, and 36.4% in those with triple-negative tumors. The pathological complete response rate at surgery was 15% (95% CI=6.1% to 24.4%). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6%), grade 2/3 leukocytopenia in 29 (43.9%) and grade 2/3 liver dysfunction in five (7.5%). Conclusion: Weekly neoadjuvant Nab-PTX at 100 mg/m2 led to good response rates (59.1%) and was well tolerated.

Original languageEnglish
Pages (from-to)6481-6488
Number of pages8
JournalAnticancer research
Volume37
Issue number11
DOIs
Publication statusPublished - 2017 Nov
Externally publishedYes

Keywords

  • Breast cancer
  • HER2-negative
  • Nanoparticle albumin-bound paclitaxel
  • Pathological complete response
  • Response rate
  • Upfront chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Matsui, A., Tatibana, A., Suzuki, N., Hirata, M., Oishi, Y., Hamaguchi, Y., Murata, Y., Nagayama, A., Iwata, Y., & Okamoto, Y. (2017). Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer. Anticancer research, 37(11), 6481-6488. https://doi.org/10.21873/anticanres.12104